Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin.

Cymbaluk-Płoska A, Sobolewski P, Chudecka-Głaz A, Wiśniewska E, Łapczuk J, Frankowski M, Droździk M, El Fray M.

J Funct Biomater. 2019 Dec 6;10(4). pii: E55. doi: 10.3390/jfb10040055.

2.

Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.

Menkiszak J, Chudecka-Głaz A, Cymbaluk-Płoska A, Celewicz A, Kojs Z, Szajda M, Świniarska M, Bedner R, Jurczak A, Celewicz M, Cieszyńska M, Lubiński J, Gronwald J.

Hered Cancer Clin Pract. 2019 Mar 14;17:10. doi: 10.1186/s13053-019-0109-5. eCollection 2019.

3.

The role of lipocalin-2 serum levels in the diagnostics of endometrial cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Machaliński B, Sompolska-Rzechuła A, Kwiatkowski S, Menkiszak J.

Cancer Biomark. 2019;24(3):315-324. doi: 10.3233/CBM-181942.

4.

Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.

Szarszewska M, Markowska A, Jach R, Marszałek A, Filas V, Bednarek W, Olejek A, Tomczak P, Sajdak S, Nowak-Markwitz E, Jaszczyńska-Nowinka K, Stanisławiak-Rudowicz J, Gryboś A, Chudecka-Głaz A, Gryboś M, Adamska K, Ramlau R, Markowska J, Knapp P.

Adv Med Sci. 2019 Sep;64(2):235-240. doi: 10.1016/j.advms.2018.12.007. Epub 2019 Feb 26.

PMID:
30822630
5.

sFlt-1/PlGF and Doppler ultrasound parameters in SGA pregnancies with confirmed neonatal birth weight below 10th percentile.

Kwiatkowski S, Bednarek-Jędrzejek M, Ksel J, Tousty P, Kwiatkowska E, Cymbaluk A, Rzepka R, Chudecka-Głaz A, Dołęgowska B, Torbè A.

Pregnancy Hypertens. 2018 Oct;14:79-85. doi: 10.1016/j.preghy.2018.08.448. Epub 2018 Aug 17.

PMID:
30527123
6.

Risk Model in Women with Ovarian Cancer Without Mutations.

Cymbaluk-Płoska A, Chudecka-Głaz A, Sompolska-Rzechuła A, Rasinska K, Dubiel P, Menkiszak J.

Open Med (Wars). 2018 Nov 25;13:565-574. doi: 10.1515/med-2018-0084. eCollection 2018.

7.

Clinical efficacy of p16/Ki-67 dual-stained cervical cytology in secondary prevention of cervical cancer.

Celewicz A, Celewicz M, Wężowska M, Chudecka-Głaz A, Menkiszak J, Urasińska E.

Pol J Pathol. 2018;69(1):42-47. doi: 10.5114/pjp.2018.75335.

8.

Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?

Chudecka-Głaz A, Cymbaluk-Płoska A, Wężowska M, Menkiszak J.

PLoS One. 2018 Mar 27;13(3):e0194270. doi: 10.1371/journal.pone.0194270. eCollection 2018.

9.

Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Jagodzińska A, Pius-Sadowska E, Sompolska-Rzechuła A, Machaliński B, Menkiszak J.

Onco Targets Ther. 2018 Mar 13;11:1363-1372. doi: 10.2147/OTT.S155942. eCollection 2018.

10.

Circulating Serum Level of Visfatin in Patients with Endometrial Cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Sompolska-Rzechuła A, Machaliński B, Menkiszak J.

Biomed Res Int. 2018 Jan 4;2018:8576179. doi: 10.1155/2018/8576179. eCollection 2018.

11.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.

Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.

12.

Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Machaliński B, Menkiszak J, Sompolska-Rzechuła A.

J Ovarian Res. 2018 Jan 5;11(1):1. doi: 10.1186/s13048-017-0373-9.

13.

Implementation of an enhanced recovery after surgery (ERAS) protocol in a gynaecology department - the follow-up at 1 year.

Nikodemski T, Biskup A, Taszarek A, Albin M, Chudecka-Głaz A, Cymbaluk-Płoska A, Menkiszak J.

Contemp Oncol (Pozn). 2017;21(3):240-243. doi: 10.5114/wo.2017.69589. Epub 2017 Sep 29.

14.

Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Sompolska-Rzechuła A, Chudecka K, Bulsa M, Machaliński B, Menkiszak J.

Dis Markers. 2017;2017:6589262. doi: 10.1155/2017/6589262. Epub 2017 Sep 27.

15.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.

JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.

16.

Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Sompolska-Rzechuła A, Machaliński B, Surowiec A, Menkiszak J.

Onco Targets Ther. 2017 Jun 27;10:3169-3175. doi: 10.2147/OTT.S136750. eCollection 2017.

17.

Thrombospondin-I concentrations behavior in plasma of patients with ovarian cancer.

Cymbaluk-Płoska A, Chudecka-Głaz A, Pius-Sadowska E, Machaliński B, Menkiszak J.

Cancer Biomark. 2017 Jul 19;20(1):31-39. doi: 10.3233/CBM-161546.

PMID:
28655131
18.

Ectopic pregnancy treatment by combination therapy.

Cymbaluk-Płoska A, Chudecka-Głaz A, Kuźniak S, Menkiszak J.

Open Med (Wars). 2016 Dec 16;11(1):530-536. doi: 10.1515/med-2016-0091. eCollection 2016.

19.

HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.

Chudecka-Głaz A, Cymbaluk-Płoska A, Strojna A, Menkiszak J.

Dis Markers. 2017;2017:9792756. doi: 10.1155/2017/9792756. Epub 2017 Jan 15.

20.

Supplemental Content

Loading ...
Support Center